

October 23, 2020

Abiomed Inc. % Ken Ryder Senior Director Global Regulatory Affairs 1500 John Ave Suite 190 Halethorpe, Maryland 21227

Re: K200109

Trade/Device Name: OXY-1 System Regulation Number: 21 CFR 870.4350 Regulation Name: Cardiopulmonary Bypass Oxygenator Regulatory Class: Class II Product Code: DTZ, KFM, DWA, DWF Dated: September 21, 2020 Received: September 22, 2020

Dear Ken Ryder:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see

https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <u>https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems</u>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</u>) and CDRH Learn (<u>https://www.fda.gov/training-and-continuing-education/cdrh-learn</u>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</u>) for more information or contact DICE by email (<u>DICE@fda.hhs.gov</u>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Fernando Aguel Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number *(if known)* K200109

Device Name OXY-1 System

Indications for Use (Describe)

The OXY-1 System is intended to be used for extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to 6 hours in duration

| Type of Use | (Select one or both | n, as applicable) |
|-------------|---------------------|-------------------|
|-------------|---------------------|-------------------|

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov*

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Product: Oxy-1 System Section: 5 – 510(k) Summary

510(k) Summary

I. SUBMITTER

Abiomed, Inc. 22 Cherry Hill Dr. Danvers, MA 01923 Phone: 978-646-1707

Contact Person: J. Kenneth Ryder Date Prepared: October 21, 2020

II. DEVICE

Name of Device: OXY-1 System Common or Usual Name: OXY-1 System Classification Name: Cardiopulmonary bypass oxygenator Regulatory Class: II Product Code: DTZ – Oxygenator, Cardiopulmonary Bypass KFM – Pump, Blood, Cardiopulmonary Bypass, Non-Roller Type DWA – Control, Pump Speed, Cardiopulmonary Bypass DWF – Catheter, Cannula and Tubing, Vascular, Cardiopulmonary Bypass

III. PREDICATE DEVICE(S)

Medtronic Affinity NT (Model 511) Oxygenator (K191029) Maquet, Rotaflow Pump (K991864) Maquet, Rotaflow Console (K991864) Maquet, HLM Tubing Set with Bioline coating (K080592)

IV. DEVICE DESCRIPTION

The Breethe[®] OXY-1 System provides extracorporeal circulation for full or partial cardiopulmonary bypass support for up to six hours. The OXY-1 System includes; a disposable pump and oxygenator, a pump driver, blood tubing, and a console for powering and controlling the pump and managing gas flow. These components are designed to operate together to reduce the overall equipment footprint at the bedside.

V. INDICATION FOR USE

The OXY-1 System is indicated for:

OXY-1 System The OXY-1 System is intended to be used for extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to 6 hours in duration.

The identified predicates are indicated for the following:

| Product: Oxy-1 System Section: 5 – 510(k) Sum | | Firm: Abiomed, Inc. Page 2 of 5 |
|--|---|--|
| Medtronic - Affinity NT 511 (K191029) | The AFFINITY [®] NT Hollow Fiber Oxygenator with Plasma Resist used in an extracorporeal perfusion circuit to oxygenate and from the blood and to cool or warm the blood during routine procedures up to 6 hours in duration. | remove carbon dioxide |
| Maquet - Rotaflow Pump – RF 32 (K991864) | The Rotaflow centrifugal pump system is intended for use in circuit to pump blood during short duration cardiopulmonary 6 hours or less. | · · |
| Maquet - Rotaflow Console (K991864) | The Rotaflow centrifugal pump system is intended for use in circuit to pump blood during short duration cardiopulmonary 6 hours or less. | · · |
| Maquet - HLM Tubing Set with Bioline coating (K080592) | The HLM Tubing Sets with Bioline Coating are designed to be circulation during cardiopulmonary bypass procedures lasting | • |

The subject device and the identified predicates have the same intended use for extracorporeal circulation during full or partial cardiopulmonary bypass. The Indications for Use for the OXY-1 System is substantially equivalent to the predicate devices. Differences do not alter the intended therapeutic use of the device nor do they affect the safety and effectiveness of the device relative to the predicates.

VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE

| Oxygenator Technological | Subject Device | Predicate Device Medtronic - Affinity NT 511 (K191029) | |
|---|---|---|--|
| Characteristics / Performance Specifications | Oxy-1 System (PLU Disposable) | | |
| Materials | | | |
| Membrane | Polymethylpentene | Polypropylene | |
| Housing | Polycarbonate | Polycarbonate | |
| Potting | Urethane | Urethane | |
| Design | | | |
| Heat Exchanger | No | Yes | |
| Membrane Type | Hollow Fiber | Hollow Fiber | |
| Effective Membrane Surface | 2.4 m2 | 2.5 m2 | |
| Area | | | |
| Gas Pathway | Two Gas Pathways | Single Gas Pathway | |
| Oxygenator Geometry | Cylindrical | Cylindrical | |
| Tubing Connectors | 3/8" | 3/8″ | |
| Priming Volume (Oxygenator Only) | 285 ml | 215 ml | |
| Sterile | SAL 10^-6 | SAL 10^-6 | |
| Sterilization method | Ethylene Oxide | Ethylene Oxide | |
| Performance Specifications | | | |
| Blood Flow Rate | 0.5-5.0 Lpm | 0.5 – 7.0 Lpm | |
| Gas Transfer | Tested per "Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions" Dated November 13, 2000 | Tested per "Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions" Dated November 13, 2000 | |
| Hemolysis | Average NIH of 0.0210 mg/100L | Average NIH of 0.0318 mg/100L | |
| Pressure Drop (at 5 Lpm) | Average of 38 mmHg | Average of 52 mmHg | |

| Centrifugal Pump | Subject Device | Predicate Device |
|--|-------------------------------|--|
| Technological Characteristics / Performance Specifications | Oxy-1 System (PLU Disposable) | Maquet - Rotaflow Pump – RF 32 (K991864) |
| Materials | | |
| Housing | Polycarbonate | Polycarbonate |
| Impeller | Polycarbonate | Polycarbonate |
| Bearing | Polyethylene, Sapphire | Polyethylene, Sapphire |
| Design | | |
| Pump Operation | Centrifugal pump | Centrifugal pump |
| Coupling | Magnetic | Magnetic |
| Bearing | Single pivot | Single pivot |
| Priming Volume (Pump Only) | 34ml | 32ml |
| Tubing Connectors | 3/8″ | 3/8" |
| Sterile | SAL 10^-6 | SAL 10^-6 |
| Sterilization method | Ethylene Oxide | Ethylene Oxide |
| Performance Specifications | | |
| Blood Flow Rate | 0.5-5.0 Lpm | 0.5 – 9.0 Lpm |
| Hemolysis | Average NIH of 0.0210 mg/100L | Average NIH of 0.0318 mg/100L |

| Controller & Driver | Subject Device | Predicate Device |
|--|------------------------|-------------------------------------|
| Technological Characteristics / Performance Specifications | Oxy-1 System (Console) | Maquet - Rotaflow Console (K991864) |
| Design | · | |
| Coupling | Magnetic | Magnetic |
| Energy Source | Battery / Mains | Battery / Mains |
| Other features | | |
| Sweep Gas Source | Internal / External | External |
| Sighing Gas Source | Internal / External | External |
| Software | | |
| Constant RPM Mode | Yes | Yes |
| Constant Flow Mode | No | Yes |
| -Display | | |
| Blood Flow | Yes | Yes |
| Pump RPM Settings | Yes | Yes |
| Internal Sweep Gas Source | Yes | N/A |
| Settings | | |
| Alarm Limit Settings | Yes | Yes |
| -Alarms | | |
| Blood Flow | Yes | Yes |
| Bubble | Yes | Yes |
| Low Battery | Yes | Yes |
| System Failure Alarms | Yes | Yes |
| Hardware | | |
| -Bubble Sensor | Yes | Yes |
| -Flow Sensor | Yes | Yes |
| Emergency Drive Unit | Hand Crank | Hand Crank |
| Performance Specifications | | |

| Controller & Driver | Subject Device | Predicate Device |
|--|------------------------|-------------------------------------|
| Technological Characteristics / Performance Specifications | Oxy-1 System (Console) | Maquet - Rotaflow Console (K991864) |
| RPM Range | 0-4500 RPM | 0-5000 RPM |

| Blood Tubing Technological | Subject Device | Predicate Device |
|---|-------------------------------|--|
| Characteristics / Performance Specifications | Oxy-1 System (PLU Disposable) | Maquet - HLM Tubing Set with Bioline coating (K080592) |
| Materials | | |
| Tubing | Polyvinyl Chloride | Polyvinyl Chloride |
| Surface Treatment | None | Bioline (albumin and heparin) |
| Design | | |
| Tubing Connectors | 3/8″ | 3/8" |

VII. PERFORMANCE DATA

The following performance data was provided in support of the substantial equivalence determination.

Biocompatibility Testing:

Biocompatibility testing of the OXY-1 PLU Disposable was conducted for circulating blood for less than 24 hours.

Electrical safety and electromagnetic compatibility (EMC):

The system complies with the IEC 60601-1 standard for electrical safety and the IEC 60601-1-2 standard for EMC.

Software Verification and Validation Testing:

The software is classified as "major" level of concern. Testing and documentation for a "major" level of concern are provided in the submission.

Performance Testing:

The following testing was conducted as recommended in "Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions; Final Guidance for Industry and FDA Staff" dated November 13, 2000.

- Gas Transfer Testing
- Blood and Gas Path Integrity
- Hemolysis
- Hydraulic Performance
- Volatile Organic Compounds
- Particulates evaluation
- ISO 80601-2-69
- Software V&V
- Reliability
- Shelf Life

No animal studies or clinical studies were required or conducted.

Product: Oxy-1 System Section: 5 – 510(k) Summary

VIII. CONCLUSIONS

The OXY-1 System has the same intended use as the identified predicates, has been demonstrated to be substantially equivalent to the identified predicates through performance testing, and the differences do not raise different questions of safety and effectiveness.